INTELLIPHARMACEUTICS INTERNATIONAL INC. Operating Expenses
INTELLIPHARMACEUTICS INTERNATIONAL INC. reported Operating Expenses of $982.37 thousand for the 3-month period ending 2023-08-31, per its 6-K filed 2023-10-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2024-02-06
- INTELLIPHARMACEUTICS INTERNATIONAL INC. operating expenses for the quarter ending 2023-08-31 was $982.37K, a 155.00% increase year-over-year.
- INTELLIPHARMACEUTICS INTERNATIONAL INC. operating expenses for the quarter ending 2023-05-31 was $511.56K, a 59.14% decline year-over-year.
- INTELLIPHARMACEUTICS INTERNATIONAL INC. operating expenses for the quarter ending 2023-02-28 was $627.74K, a 26.69% decline year-over-year.
- INTELLIPHARMACEUTICS INTERNATIONAL INC. operating expenses for the quarter ending 2022-11-30 was $887.09K, a 36.52% decline year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2023-08-31 | $982.37K 6-K · filed 2023-10-16 | $1.49M derived: sum of 2 quarters · filed 2023-10-16 | $2.12M 6-K · filed 2023-10-16 | $3.01M derived: sum of 4 quarters · filed 2024-02-06 | |
| 2023-05-31 | $511.56K 6-K · filed 2023-09-26 | $1.14M 6-K · filed 2023-09-26 | $2.03M derived: sum of 3 quarters · filed 2024-02-06 | $2.41M derived: sum of 4 quarters · filed 2024-02-06 | |
| 2023-02-28 | $627.74K 6-K · filed 2023-09-26 | $1.51M derived: sum of 2 quarters · filed 2024-02-06 | $1.90M derived: sum of 3 quarters · filed 2024-02-06 | $3.15M derived: sum of 4 quarters · filed 2024-02-06 | |
| 2022-11-30 | $887.09K derived: 20-F/A 12 month − 6-K 9 month · filed 2024-02-06 | $1.27M derived: sum of 2 quarters · filed 2024-02-06 | $2.52M derived: sum of 3 quarters · filed 2024-02-06 | $2.92M 20-F/A · filed 2024-02-06 | |
| 2022-08-31 | $385.25K 6-K · filed 2023-10-16 | $1.64M derived: sum of 2 quarters · filed 2023-10-16 | $2.03M 6-K · filed 2023-10-16 | $2.43M 6-K · filed 2022-10-14 | $3.89M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-05-31 | $1.25M 6-K · filed 2023-09-26 | $2.04M 6-K · filed 2023-09-26 | $3.51M derived: sum of 3 quarters · filed 2024-02-06 | $4.59M derived: sum of 4 quarters · filed 2024-02-06 | |
| 2022-02-28 | $856.33K 6-K · filed 2023-09-26 | $2.25M derived: sum of 2 quarters · filed 2024-02-06 | $3.34M derived: sum of 3 quarters · filed 2024-02-06 | $4.34M derived: sum of 4 quarters · filed 2024-02-06 | |
| 2021-11-30 | $1.40M derived: 20-F/A 12 month − 6-K 9 month · filed 2024-02-06 | $2.48M derived: sum of 2 quarters · filed 2024-02-06 | $3.48M derived: sum of 3 quarters · filed 2024-02-06 | $4.17M 20-F/A · filed 2024-02-06 | |
| 2021-08-31 | $1.08M 6-K · filed 2022-10-14 | $2.08M derived: sum of 2 quarters · filed 2022-10-14 | $2.78M 6-K · filed 2022-10-14 | ||
| 2021-05-31 | $1.00M 6-K · filed 2022-07-21 | $1.79M 6-K · filed 2022-07-21 | |||
| 2021-02-28 | $784.91K 6-K · filed 2022-04-14 | ||||
| 2020-11-30 | $6.08M 20-F/A · filed 2024-02-06 | ||||
| 2019-11-30 | $11.28M 20-F/A · filed 2022-05-09 |